Evaluation of relationship between disease severity, mean platelet volume, and platelet distribution width in stable chronic obstructive pulmonary disease

Yıl 2018, Cilt: 3 Sayı:3, 132 - 137, 30.11.2018

Pelin Uysal

https://doi.org/10.25000/acem.444456

Öz

Aim: This study was conducted to evaluate the relationship between
disease severity, mean platelet volume and platelet distribution width in
stable chronic obstructive pulmonary disease.

Methods: The study included 120 consecutive patients with stable chronic
obstructive pulmonary disease and 30 consecutive
age-matched healthy subjects (control
group). Patients
were classified as A (mild), B (mild to moderate), C (moderate to severe) and D
(severe) defined by the GOLD committee and grouped as A/B (n= 60) and C/D
(n=60).

Results: Platelet levels were not different among the groups. Mean
platelet volume was lower in all patients than control group (p=0.001). Level
of platelet distribution width was higher in all patients than control group (p=0.018).
Mean platelet volume in C/D groups were significantly lower than A/B group (p=0.011)
and control group (p=0.001). Mean platelet volume in A/B group were also significantly
lower than control group (p=0.001). Erythrocyte sedimentation rates were higher
in A/B and C/D groups than control group (p=0.007 and p=0.001, respectively). C-reactive
protein levels in control group were significantly lower than C/D group (p=0.001).
No statistically significant correlations were observed between mean platelet volume and forced
expiratory volume in one second and forced expiratory volume in one second/forced
vital capacity or between mean platelet volume and other inflammatory
parameters in A/B or C/D groups. Significant positive
correlations were found between erythrocyte sedimentation rate and C-reactive
protein (r=0.375; p=0.003), and between mean platelet volume and platelet
large cell ratio (r=0.749; p=0.001) in
C and D groups.

Conclusion: It was concluded that mean platelet volume could be used as a negative acute‑phase
reactant in evaluation of disease
severity of chronic obstructive pulmonary disease as C-reactive protein. 

Anahtar Kelimeler

Chronic obstructive pulmonary disease, mean platelet volume, platelet distribution width, forced expiratory volume, forced vital capacity

Stabil kronik obstrüktif akciğer hastalığında ortalama trombosit hacmi ve trombosit dağılım genişliğinin hastalık şiddeti ile ilişkisinin değerlendirilmesi

Öz

Amaç: Bu çalışmada kronik obstrüktif akciğer hastalığında ortalama
trombosit hacmi ve trombosit dağılım genişliği ile hastalık şiddeti arasındaki
ilişkinin değerlendirilmesi amaçlandı.

Yöntemler: Çalışmaya 120 ardışık kronik obstrüktif akciğer hastası ve
yaşları eşleştirilmiş 30 ardışık sağlıklı kişi (kontrol grubu) alındı. GOLD komitesi
tarafından tanımlanan kronik obstrüktif
akciğer hastalığı şiddetini belirlemek için hastalar A (hafif), B (hafif-orta),
C (orta-şiddetli) ve D (şiddetli) olarak sınıflandı ve A/B (n=60) ve C/D (n=60)
olarak gruplandı.

Bulgular: Gruplar arasında trombosit düzeylerinin istatistiksel olarak
anlamlı olmadığı bulundu. Ortalama trombosit hacmi tüm hastalarda kontrollere
göre daha düşüktü (p=0.001). Tüm hastalarda trombosit
dağılım genişliği düzeyleri kontrol grubundan daha yüksekti (p=0.018). Ortalama trombosit
hacmi C/D grubunda, A/B grubu (p=0.011) ve kontrol grubundan (p=0.001) anlamlı olarak düşük
bulundu. Ortalama trombosit hacmi, A/B
grubunda kontrol grubundan anlamlı derecede düşük bulundu (p=0.001). Eritrosit sedimantasyon
hızı A/B ve C/D gruplarında kontrol
grubundan daha yüksek iken (sırasıyla, p=0.007 ve p=0.001). C-reaktif protein düzeyleri kontrol grubunda C/D grubundan anlamlı
derecede düşük bulundu (p=0.001). A/B veya C/D
gruplarında ortalama trombosit hacmi ile bir saniyedeki zorlu ekspiratuar
hacim, bir saniyedeki zorlu ekspiratuar hacim/zorlu vital kapasite oranı ve
diğer inflamatuar parametreler arasında istatistiksel olarak anlamlı bir ilişki
görülmedi. C/D grubunda eritrosit
sedimantasyon hızı, C-reaktif protein düzeyleri (r=0.375; p=0.003) ile ve ortalama
trombosit hacmi de büyük hücreli platelet oranı ile (r=0.749; p=0.001) pozitif korelasyon gösterdi.

Sonuç: Bu çalışma kronik obstrüktif akciğer hastalığında klasik pozitif
akut faz reaktanı C-reaktif proteinin yanı sıra düşük ortalama trombosit hacmi’nin
hastalık şiddetinin değerlendirilmesinde negatif akut faz reaktanı olarak
kullanılabileceğini düşündürmektedir. 

Anahtar Kelimeler

Kronik obstrüktif akciğer hastalığı, ortalama trombosit volümü, trombosit dağılım genişliği, zorlu ekspiratuar hacim, zorlu vital kapasite

Kaynakça

• 1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-85.
• 2. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483.
• 3. Nakstad B, Lyberg T, Skjonsberg OH. Boye NP. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res. 1990;57:827-38.
• 4. Rostagno C, Prisco D, Boddi M, Poggesi L. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J. 1991;4:147-51.
• 5. Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets. 2008;19:405-8.
• 6. Arica S, Ozer C, Arica V, Karakus A, Celik T, Gunesacar R. Evaluation of the mean platelet volume in children with familial Mediterranean fever. Rheumatol Int. 2011;32:3559-63.
• 7. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157-61.
• 8. Agapakis DI, Massa EV, Hantzis I, Maraslis S, Alexiou E, Imprialos KP, et al. The Role of Mean Platelet Volume in Chronic Obstructive Pulmonary Disease Exacerbation. Respir Care.2016;61:44-9.
• 9. Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18:1244-8.
• 10. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol. 2009;31:277-97.
• 11. Mahdavi-Zafarghandi R, Shakiba B, Keramati MR, Tavakkoli M. Platelet volume indices in patients with varicocele. Clin Exp Reprod Med. 2014;41:92-5.
• 12. Wang M, Zhang J, Ji Q, Yang Q, Zhao F, Li W, et al. Evaluation of platelet distribution width in chronic obstructive pulmonary disease patients with pulmonary embolism. Biomark Med. 2016;10:587-96.
• 13. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-65.
• 14. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, et al.; Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) Scientific Committee. Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975-82.
• 15. Schou L, Østergaard B, Rasmussen LS, Rydahl-Hansen S, Jakobsen AS, Emme C, et al. Telemedicine-based treatment versus hospitalization in patients with severe chronic obstructive pulmonary disease and exacerbation: effect on cognitive function. A randomized clinical trial. Telemed J E Health. 2014;20:640-6.
• 16. Milacić N, Milacić B, Milojković M, Ljubisavljevći S, Vodopić S, Hasanbegović M, et al. Correlation of C-reactive protein and COPD severity. Acta Clin Croat. 2016;55:41-8.
• 17. Simonovska L, Ahmeti I, Mitreski V. Evaluation of C-Reactive Protein in Patients with Chronic Obstructive Pulmonary Disease. Open Access Maced J Med Sci. 2015;3:283-6.
• 18. Kurtipek E, Bekci TT, Kesli R, Sami SS, Terzi Y. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. J Pak Med Assoc. 2015;65:1283-7.
• 19. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-74.
• 20. Białas AJ, Pedone C, Piotrowski WJ, Antonelli Incalzi R. Platelet distribution width as a prognostic factor in patients with COPD - pilot study. Int J Chron Obstruct Pulmon Dis. 2017;12:2261-7.
• 21. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.
• 22. Kim DS, Lee J, Kim SH, Kim SM, Lee MG. Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med J. 2015;56:712-8.
• 23. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75:291-4.
• 24. Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18:1244-8.
• 25. Makhlouf HA, Sadek SH, Nafady AAH. Platelet function in diabetic and nondiabetic patients with chronic obstructive pulmonary disease: a case control study. Clin Respir J. 2018;12:48-56.
• 26. Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122:284-90.
• 27. Karadeniz G, Aktoğu S, Erer OF, Kır SB, Doruk S, Demir M, et al. Predictive value of platelet to lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. Biomarkers. 2016;10:701-10.
• 28. Kalemci S, Akin F, Sarihan A, Sahin C, Zeybek A, Yilmaz N. The relationship between hematological parameters and the severity level of chronic obstructive lung disease. Pol Arch Intern Med. 2018;128:171-7.
• 29. Steiropoulos P, Papanas N, Nena E, Xanthoudaki M, Goula T, Froudarakis M, et al. Mean platelet volume and platelet distribution width in patients with chronic obstructive pulmonary disease: the role of comorbidities. Angiology. 2013;64:535-9.
• 30. Cui H, Liu L, Wei Z, Wang D, Hu Y, Hu G, et al. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr. 2012;54:e109 e112.
• 31. Zheng YG, Yang T, Xiong CM, He JG, Liu ZH, Gu Q, et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2015;24:566-72.
• 32. Farah R, Ibrahim R, Nassar M, Najib D, Zivony Y, Eshel E. The neutrophil / lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. Panminerva Med. 2017;59:203-9.
• 33. Bansal R, Gupta HL, Goel A, Yadav M. Association of increased platelet volume in patients of chronic obstructive pulmonary disease: clinical implications. J Indian Acad Clin Med. 2002;3:169–72.
• 34. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769-74.
• 35. Koc I, Karatas ZA, Mandollu E, Mermer A, Kaya A, Dokme A, et al. Importance of mean platelet volume in patients with chronic obstructive pulmonary disease. Gaziantep Med J. 2014;20:294-8.